Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 1,743 trials

Pancreatic Cancer: Short vs. Long Chemotherapy

We are comparing two lengths of chemotherapy before surgery for patients with borderline and locally advanced pancreatic cancer. Our goal is to find out which duration may help improve survival rates.

Advanced Pancreatic Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyOncology

Glioblastoma: [177Lu]Lu-NeoB Treatment Study

We are exploring a new radioactive treatment for patients with newly diagnosed glioblastoma, and testing it alone for those whose cancer has returned. The goal is to find the best dose and understand its effects.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Calcific Aortic Valve Stenosis: Pelacarsen (TQJ230) Study

We are studying whether the medication pelacarsen can slow the progression of calcific aortic valve stenosis in patients with high lipoprotein(a) levels. This trial will help us understand its effects compared to a placebo.

Calcific Aortic Valve Stenosis>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Aggressive B-cell Non-Hodgkin Lymphomas: REGN5837 and Odronextamab

We are studying the safety of a new treatment combination for adults with aggressive B-cell non-Hodgkin lymphomas. This trial aims to see how well these medications work together.

B-cell Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)HematologyOncology

Neuroendocrine Tumors: 177Lu-edotreotide vs. Everolimus

We are studying whether a new treatment, 177Lu-edotreotide, can help patients with neuroendocrine tumors of the lung and thymus live longer without disease progression compared to everolimus.

Neuroendocrine Tumor>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Hydroxychloroquine for Extra-pulmonary Sarcoidosis

We are studying whether hydroxychloroquine can reduce the need for steroids in patients with extra-pulmonary sarcoidosis. This trial will also look at its effects on quality of life and potential side effects.

Sarcoidosis>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineRheumatology

Chronic Graft-Versus-Host Disease: Axatilimab and Ruxolitinib Study

We are studying a new treatment combining axatilimab and ruxolitinib for people newly diagnosed with chronic graft-versus-host disease. The goal is to see if this combination is safe and effective in improving their condition.

Chronic Graft-Versus-Host Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementAllergologyHematologyInternal Medicine

Bladder Cancer Treatment: Chemoablation vs. Standard Care

We are studying whether a new chemoablation method is more effective than standard bladder surgery and chemotherapy for patients with recurrent non-muscle invasive bladder cancer. This may help reduce recurrence rates and improve long-term outcomes.

Recurrent Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

Hodgkin Lymphoma: Tislelizumab with Gemcitabine and Cisplatin

We are studying a combination of tislelizumab, gemcitabine, and cisplatin for patients with relapsed or refractory Hodgkin lymphoma. The goal is to see if this treatment improves survival and response rates.

Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Heart Failure: Comparing Spironolactone and Eplerenone

We are studying whether spironolactone or eplerenone is more effective in reducing the risk of death for patients with heart failure. This trial is for those receiving treatment in a heart failure clinic.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced NSCLC: Comparing Immune Treatments

We are studying two treatment strategies for patients with advanced non-small cell lung cancer to see which one works better. This trial also examines how these treatments affect the immune system and collects samples for future research.

Non-Small Cell Lung Cancer Stage IV>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

Prostate Cancer: Metastasis-Directed Therapy Study

We are investigating if a new treatment can improve survival for men with castration-refractory prostate cancer and a few progressive lesions. This study compares the new approach to standard care to see which is more effective.

Oligoprogressive Metastatic Castration-Refractory Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Infliximab for Non-Crohn Anal Fistulas

We are studying whether Infliximab can improve healing in patients with complex anal fistulas after surgery. This trial aims to find out if this treatment helps reduce complications and improve recovery.

Anal Fistula>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

Pramipexole for Anhedonic Depression

We are studying the long-term effects of adding pramipexole to treatment for people with anhedonic depression. The goal is to see how well it works and how well patients tolerate it.

Depression>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

AR Positive Triple-Negative Breast Cancer: Bicalutamide and Abemaciclib Study

We are studying a combination of bicalutamide and abemaciclib for patients with AR positive triple-negative breast cancer. The goal is to see if this treatment helps control the disease and to evaluate its safety.

Locally Advanced Unresectable or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Open Angle Glaucoma: Citicoline Eye Drops

We are studying whether citicoline eye drops can help preserve vision in patients with open angle glaucoma. The trial also looks at the safety of these drops and their effects on eye structure.

Glaucoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hydroceles and Spermatoceles: Comparing Sclerotherapy Treatments

We are studying two methods of sclerotherapy to see which one better reduces symptoms and requires fewer follow-up treatments. This trial also looks at pain levels during the procedure with and without local anesthesia.

SpermatoceleHydrocele>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesUrology

Lupus in Children: Anifrolumab Study

We are studying the safety and effectiveness of anifrolumab in children and teens with moderate to severe lupus. This trial aims to find the right dose and see how well it works compared to a placebo.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePediatricsRheumatology

Lymphoma Treatment: STP938

We are testing a new drug called STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas. The goal is to see if it can provide a new treatment option for those who have not responded to other therapies.

B-cell LymphomaT-cell Lymphoma>2 yearsSafety phase (I)HematologyOncology